Home › Funds › Timothy G. Youngquist 2020 Irrevocable Trust › CHRS

Timothy G. Youngquist 2020 Irrevocable Trust position in CHRS

COHERUS ONCOLOGY INC · Health Care

Timothy G. Youngquist 2020 Irrevocable Trust reported holding 13,050,623 shares of CHRS (COHERUS ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$15.8M, representing 3.22% of its reported portfolio and ranking #4 among its reported holdings. Timothy G. Youngquist 2020 Irrevocable Trust has disclosed CHRS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)13.05M sh
Reported value held$15.79M
Portfolio Weight3.22%
First reportedQ4 2025
Last changeAdd
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Timothy G. Youngquist 2020 Irrevocable Trust's CHRS position evolved

Timothy G. Youngquist 2020 Irrevocable Trust first disclosed a stake in CHRS in Q4 2025 at 5,895,349 shares (US$8.4M). The position peaked in Q3 2026 at 13,050,623 shares, worth US$15.8M. Across 4 filings, Timothy G. Youngquist 2020 Irrevocable Trust increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 13,050,623 shares valued at US$15.8M — an increase of 12,850,623 shares quarter over quarter.. Notable position changes include a 92% trim in Q1 2026 (shares fell 17% over the following quarter), a 57% trim in Q2 2026 (shares fell 14% over the following quarter), a 6425% increase in Q3 2026 (shares fell 33% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 5.90M $8.37M New
Q1 2026 460.00K $75.00K Reduce
Q2 2026 200.00K $25.00K Reduce
Q3 2026 13.05M $15.79M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CHRS and 13F data

CHRS (COHERUS ONCOLOGY INC) is a Health Care company. 20 other funds we track also report a position in CHRS — the largest reported positions include Samsara BioCapital, LLC (US$4.8M), Kohlberg Kravis Roberts & Co. L.P. (US$4.2M), CM Management, LLC (US$2.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CHRS

All CHRS fund holders →

FAQ

How long has Timothy G. Youngquist 2020 Irrevocable Trust held CHRS?

Timothy G. Youngquist 2020 Irrevocable Trust has disclosed CHRS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Timothy G. Youngquist 2020 Irrevocable Trust's current position in CHRS?

As of Q3 2026, Timothy G. Youngquist 2020 Irrevocable Trust holds 13.05M shares of CHRS (COHERUS ONCOLOGY INC), valued at $15.79M, representing 3.22% of its reported portfolio and ranking #4.

Has Timothy G. Youngquist 2020 Irrevocable Trust been buying or selling CHRS?

In the latest 13F filing (Q3 2026), Timothy G. Youngquist 2020 Irrevocable Trust increased its position in CHRS. The position peaked in Q3 2026 at 13.05M shares.

Which other funds hold CHRS?

Other major institutional holders of CHRS include Samsara BioCapital, LLC, Kohlberg Kravis Roberts & Co. L.P., CM Management, LLC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.